Text Size

Analysis of Genes That Predispose People to Develop High Blood Pressure

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00522119
First received: August 27, 2007
Last updated: July 15, 2008
Last verified: August 2007
History of Changes
  Purpose

High blood pressure affects nearly one third of all individuals in the United States. It is believed that genetic factors may predispose some people to develop this disease. This study will identify and characterize variations in three genes known to play a part in the development of high blood pressure.


Condition
Hypertension

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Genetic and Functional Analyses of Chromosome 1 Hypertension Susceptibility

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: August 2003
Study Completion Date: July 2006
Detailed Description:

High blood pressure is one of the most common health problems in this country. It can be caused by many factors, including stress, diet, diabetes, kidney disease, or obesity. In many people, there is no identifiable cause for their high blood pressure. If high blood pressure goes untreated, it can lead to heart failure, kidney failure, or stroke. Previous studies have shown that variations in three genes in chromosome 1—ATP1B1, RGS5, and SELE—cause some people to be more susceptible to developing high blood pressure. All three of these genes are involved in the development of proteins that play a role in regulating blood pressure, but it is not known exactly how variations in these genes affect blood pressure levels. This study will examine previously collected genetic samples from participants in two clinical trials, the GenNet study and the Heredity and Phenotype Interaction (HAPI) Heart study. Study researchers will analyze the samples to identify and characterize variations in the ATP1B1, RGS5, and SELE genes. Results from this study may lead to more effective diagnostic and treatment options for people with high blood pressure.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participants in the GenNet and HAPI Heart studies (genetic samples will be examined)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00522119

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Principal Investigator: Yen Pei C. Chang, PhD University of Maryland, Baltimore County
  More Information

Additional Information:
Click here for the HAPI Heart Study Web site  This link exits the ClinicalTrials.gov site
Click here for the Family Blood Pressure Program Web site  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00522119     History of Changes
Other Study ID Numbers: 1403, R01 HL088120-01A1
Study First Received: August 27, 2007
Last Updated: July 15, 2008
Health Authority: United States: Federal Government

Keywords provided by National Heart, Lung, and Blood Institute (NHLBI):
Essential Hypertension
High Blood Pressure

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on June 17, 2013